Transgene Biotek — 360° view

Transgene Biotek, a company in the Healthcare Service Provider industry, reported revenue of ₹0.06 crore and a net loss of ₹0.35 crore for the September 2026 quarter.

Transgene Biotek (BSE: TRABI) closed at ₹2.44 on 20 Nov 2026, down 32.2% over the past year. Its market capitalisation is ₹18 crore.

Share price
₹2.44 (20 Nov 2026)
Market cap
₹18 Cr (20 Nov 2026)
Revenue
₹0 Cr (September 2026 quarter)
Net profit
₹-0 Cr (September 2026 quarter)
ROCE
-2.36% (FY26)
ROE
-17.9% (FY26)
Book value
₹1.01 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹3.97 / ₹1.83 (20 Nov 2026)
1-year return
-32.2% (to 20 Nov 2026)
Sector
Healthcare
Industry
Healthcare Service Provider
Symbol
BSE: TRABI

Incorporated in 1990, Transgene Biotek Ltd is in the business of Research & Development

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.